Stephen Gruber

Has grant

Professor

City Of Hope National Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Integration of epidemiology, pathology, immunology and outcomes in colorectal cancer

Open Date: 2022-09-22

Close Date: 2027-08-31

Grant: Close

Precision Approaches to Refining TP53-associated Cancer Risk

Open Date: 2019-09-01

Close Date: 2024-08-01

Grant: Close

The Epidemiology of Immune Responses in Colorectal Cancer

Open Date: 2015-08-01

Close Date: 2020-07-31

Grant: Close

Cancer Genetics Professional Education in a Global Community of Practice

Open Date: 2013-09-01

Close Date: 2023-08-01

Grant: Close

Translational Research in GI Cancer

Open Date: 2010-09-13

Close Date: 2017-08-31

Articles (31)

Year:

2026

Introduction There is convincing evidence that overall adiposity increases the risks of several cancers. Whether the distribution of adiposity plays a similar role is unclear. Methods We used 2-sample Mendelian randomization (MR) to examine causal relationships of 5 adiposity distribution traits (abdominal subcutaneous adipose tissue (ASAT); visceral adipose tissue (VAT); gluteofemoral adipose tissue (GFAT); liver fat; and pancreas fat) with the risks of 12 obesity-related cancers (endometrial, ovarian, breast, colorectal, pancreas, multiple myeloma, liver, kidney (renal cell), thyroid, gallbladder, esophageal adenocarcinoma, and meningioma). Results Sample size across all genome-wide association studies (GWAS) ranged from 8407 to 728 896 (median: 57 249). We found evidence that higher genetically predicted ASAT increased the risks of endometrial cancer, liver cancer, and esophageal adenocarcinoma (odds ratios (OR) and 95% confidence intervals (CI) per standard deviation (SD) higher ASAT = 1.79 (1.18 to 2.71), 3.83 (1.39 to 10.53), and 2.34 (1.15 to 4.78), respectively). Conversely, we found evidence that higher genetically predicted GFAT decreased the risks of breast cancer and meningioma (ORs and 95% CIs per SD higher genetically predicted GFAT = 0.77 (0.62 to 0.97) and 0.53 (0.32 to 0.90), respectively). We also found evidence for an effect of higher genetically predicted VAT and liver fat on increased liver cancer risk (ORs and 95% CIs per SD higher genetically predicted adiposity trait = 4.29 (1.41 to 13.07) and 4.09 (2.29 to 7.28), respectively). Discussion Our analyses provide novel insights into the relationship between adiposity distribution and cancer risk. These insights highlight the potential importance of adipose tissue distribution alongside maintaining a healthy weight for cancer prevention.

Year:

2025

Supplementary Figure S5 shows the age-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.

Year:

2025

Supplementary Figure S4 shows the family-history-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.

Year:

2025

Background: Currently known associations between common genetic variants and colorectal cancer explain less than half of its heritability of 25%. As alcohol consumption has a J-shape association with colorectal cancer risk, nondrinking and heavy drinking are both risk factors for colorectal cancer. Methods: Individual-level data was pooled from the Colon Cancer Family Registry, Colorectal Transdisciplinary Study, and Genetics and Epidemiology of Colorectal Cancer Consortium to compare nondrinkers (≤1 g/day) and heavy drinkers (>28 g/day) with light-to-moderate drinkers (1–28 g/day) in GxE analyses. To improve power, we implemented joint 2df and 3df tests and a novel two-step method that modifies the weighted hypothesis testing framework. We prioritized putative causal variants by predicting allelic effects using support vector machine models. Results: For nondrinking as compared with light-to-moderate drinking, the hybrid two-step approach identified 13 significant SNPs with pairwise r 2 > 0.9 in the 10q24.2/ COX15 region. When stratified by alcohol intake, the A allele of lead SNP rs2300985 has a dose–response increase in risk of colorectal cancer as compared with the G allele in light-to-moderate drinkers [OR for GA genotype = 1.11; 95% confidence interval (CI), 1.06–1.17; OR for AA genotype = 1.22; 95% CI, 1.14–1.31], but not in nondrinkers or heavy drinkers. Among the correlated candidate SNPs in the 10q24.2/ COX15 region, rs1318920 was predicted to disrupt an HNF4 transcription factor binding motif. Conclusions: Our study suggests that the association with colorectal cancer in 10q24.2/ COX15 observed in genome-wide association study is strongest in nondrinkers. We also identified rs1318920 as the putative causal regulatory variant for the region. Impact: The study identifies multifaceted evidence of a possible functional effect for rs1318920.

Year:

2025

Background: Tobacco smoking is an established risk factor for colorectal cancer. However, genetically defined population subgroups may have increased susceptibility to smoking-related effects on colorectal cancer. Methods: A genome-wide interaction scan was performed including 33,756 colorectal cancer cases and 44,346 controls from three genetic consortia. Results: Evidence of an interaction was observed between smoking status (ever vs. never smokers) and a locus on 3p12.1 (rs9880919, P = 4.58 × 10 −8 ), with higher associated risk in subjects carrying the GG genotype [OR, 1.25; 95% confidence interval (CI), 1.20–1.30] compared with the other genotypes (OR P = 1.72 × 10 −8 ) and 8q24.23 (rs7005722, P = 2.88 × 10 −8 ). Subjects carrying the rs4151657 TT genotype showed higher risk (OR, 1.12; 95% CI, 1.09–1.16) compared with the other genotypes (OR CADM2 (3p12.1) and ATF6B (6p21.33). Conclusions: Our study identified novel genetic loci that may modulate the risk for colorectal cancer of smoking status and intensity, linked to tumor suppression and immune response. Impact: These findings can guide potential prevention treatments.

Year:

2025

Supplementary Figure S2 shows the sex-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.

Year:

2025

Background: Mechanistic data indicate the benefit of short-chain fatty acids (SCFA) produced by gut microbial fermentation of fiber on colorectal cancer, but direct epidemiologic evidence is limited. A recent study identified SNPs for two SCFA traits (fecal propionate and butyrate-producing microbiome pathway PWY-5022) in Europeans and showed metabolic benefits. Methods: We conducted a two-sample Mendelian randomization analysis of the genetic instruments for the two SCFA traits (three SNPs for fecal propionate and nine for PWY-5022) in relation to colorectal cancer risk in three large European genetic consortia of 58,131 colorectal cancer cases and 67,347 controls. We estimated the risk of overall colorectal cancer and conducted subgroup analyses by sex, age, and anatomic subsites of colorectal cancer. Results: We did not observe strong evidence for an association of the genetic predictors for fecal propionate levels and the abundance of PWY-5022 with the risk of overall colorectal cancer, colorectal cancer by sex, or early-onset colorectal cancer (diagnosed at P = 0.03) but it did not surpass multiple testing of subgroup analysis. Conclusions: Genetic instruments for fecal propionate levels and the abundance of PWY-5022 were not associated with colorectal cancer risk. Impact: Fecal propionate and PWY-5022 may not have a substantial influence on colorectal cancer risk. Future research is warranted to comprehensively investigate the effects of SCFA-producing bacteria and SCFAs on colorectal cancer risk.

Year:

2025

Background: Polygenic risk scores (PRS) which summarize individuals’ genetic risk profile may enhance targeted colorectal cancer screening. A critical step towards clinical implementation is rigorous external validations in large community-based cohorts. This study externally validated a PRS-enhanced colorectal cancer risk model comprising 140 known colorectal cancer loci to provide a comprehensive assessment on prediction performance. Methods: The model was developed using 20,338 individuals and externally validated in a community-based cohort ( n = 85,221). We validated predicted 5-year absolute colorectal cancer risk, including calibration using expected-to-observed case ratios (E/O) and calibration plots, and discriminatory accuracy using time-dependent AUC. The PRS-related improvement in AUC, sensitivity and specificity were assessed in individuals of age 45 to 74 years (screening-eligible age group) and 40 to 49 years with no endoscopy history (younger-age group). Results: In European-ancestral individuals, the predicted 5-year risk calibrated well [E/O = 1.01; 95% confidence interval (CI), 0.91–1.13] and had high discriminatory accuracy (AUC = 0.73; 95% CI, 0.71–0.76). Adding the PRS to a model with age, sex, family and endoscopy history improved the 5-year AUC by 0.06 ( P P = 0.05) in the screening-eligible age and younger-age groups, respectively. Using a risk-threshold of 5-year SEER colorectal cancer incidence rate at age 50 years, adding the PRS had a similar sensitivity but improved the specificity by 11% ( P P = 0.04) with similar specificity. Conclusions: The proposed PRS-enhanced model provides a well-calibrated 5-year colorectal cancer risk prediction and improves discriminatory accuracy in the external cohort. Impact: The proposed model has potential utility in risk-stratified colorectal cancer prevention.

Year:

2025

Supplementary Figure S3 shows the endoscopy-history-stratified calibration on 5- and 10-year absolute risks based on the PRS-enhanced model stratified by deciles of predicted risk in GERA European ancestry participants.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (91)

Li Hsu

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Polly Newcomb

University of Washington

UNITED STATES
View details

Marc Gunter

International Agency for Research on Cancer

FRANCE
View details

Tabitha Harrison

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Konstantinos K. Tsilidis

-

UNITED KINGDOM
View details

Victor Moreno

Professor

University of Barcelona

SPAIN
View details

Marina Evangelou

Senior Lecturer in Statistics

Imperial College London

UNITED KINGDOM
View details

Emma Vincent

Academic , Professor of Molecular Metabolism

University of Bristol

UNITED KINGDOM
View details

Fränzel J.B. van Duijnhoven

Wageningen University & Research

NETHERLANDS
View details

Xiao‐Ou Shu

Vanderbilt University Medical Center

UNITED STATES
View details

Susanna Larsson

Professor at Karolinska Institutet

Karolinska Institutet

SWEDEN
View details

Juan Pablo Lewinger

Associate Professor

University of Southern California

UNITED STATES
View details

John Baron

Professor

University of North Carolina

UNITED STATES
View details

David Drew

Assistant Professor of Medicine

Massachusetts General Hospital

UNITED STATES
View details

Peter Georgeson

University of Melbourne

AUSTRALIA
View details

Qingrun Zhang

Assistant Professor

University of Calgary

CANADA
View details

Ulrike Peters

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Jihyoun Jeon

University of Michigan

UNITED STATES
View details

Yin Cao

Washington University School of Medicine

UNITED STATES
View details

Zhaozhong Zhu

Massachusetts General Hospital

UNITED STATES
View details

Matthew Devall

Assistant Professor

University of Virginia

UNITED STATES
View details

Sophia Harlid

Umea University

SWEDEN
View details

Eric Kawaguchi

Assistant Professor

University of Southern California

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Lisa Boardman

Professor of Medicine

Mayo Clinic

UNITED STATES
View details

Georgios Markozannes

Assisant professor

Imperial College London

UNITED KINGDOM
View details

Wei Zheng

-

UNITED STATES
View details

Weiqiang Lin

Professor

Zhejiang University

CHINA
View details

Elizabeth Platz

Professor

Johns Hopkins University

UNITED STATES
View details

Yingye Zheng

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Mariana C. Stern

Professor

University of Southern California

UNITED STATES
View details

Qiuyin Cai

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Christos V. Chalitsios

University of Oxford

UNITED KINGDOM
View details

Ludmila Vodickova

senior researcher

Charles University

CZECH REPUBLIC
View details

Tim Bishop

University of Leeds

UNITED KINGDOM
View details

Ran Tao

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Elizabeth Hauser

Duke University

UNITED STATES
View details

GUOCHONG JIA

Vanderbilt University

UNITED STATES
View details

Richard Hayes

Professor of Population Health and Environmental Medicine

NYU School of Medicine

UNITED STATES
View details

Mingyang Song

Associate Professor

Harvard University

UNITED STATES
View details

Stéphane Bézieau

Université de Nantes

FRANCE
View details

Giovanni Parmigiani

Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Virginia Díez-Obrero

Vrije Universiteit Amsterdam

NETHERLANDS
View details

Hongmei Nan

Professor

University of Indianapolis

UNITED STATES
View details

Zhishan Chen

staff Scientist

Vanderbilt University

UNITED STATES
View details

Sun-Seog Kweon

Chonnam National University

SOUTH KOREA
View details

Kaitlin Wade

Associate Professor in Epidemiology

University of Bristol

UNITED KINGDOM
View details

Emmanouil Bouras

Research associate

Imperial College London

UNITED KINGDOM
View details

Alicja Wolk

Professor of Nutritional Epidemiology

Karolinska Institutet

SWEDEN
View details

Anna H. Wu

Professor

University of Southern California

UNITED STATES
View details

Robert C. Grant

University Health Network

CANADA
View details

John Potter

Professor

University of Washington

UNITED STATES
View details

Xingyi Guo

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Bethany Van Guelpen

Umea University

SWEDEN
View details

Li Li

University of Virginia

UNITED STATES
View details

Iris Lansdorp-Vogelaar

Associate Professor

Erasmus University Medical Center

NETHERLANDS
View details

Philip Haycock

Senior Lecturer in Cancer Epidemiology

University of Bristol

UNITED KINGDOM
View details

Xia Jiang

Karolinska Institutet

SWEDEN
View details

Jirong Long

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Andrea Burnett-Hartman

Epidemiologist Program Director

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Wei Sun

Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Andrea Gsur

Medical University of Vienna

AUSTRIA
View details

Gianluca Severi

University of Firenze

ITALY
View details

Loic Le Marchand

Professor

University of Hawaii

UNITED STATES
View details

Edward A. Ruiz-Narváez

Associate Professor

University of Michigan School of Public Health

UNITED STATES
View details

Elom K Aglago

Imperial College London

UNITED KINGDOM
View details

David Conti

Professor

Colorado School of Public Health

UNITED STATES
View details

W. James Gauderman

professor

University of Southern California

UNITED STATES
View details

Vicente Martín-Sánchez

JEFE DE GRUPO

Universidad de León

SPAIN
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Graham Casey

University of Virginia

UNITED STATES
View details

Yaohua Yang

Assistant Professor

University of Virginia

UNITED STATES
View details

Catherine Tangen

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Satu Männistö

Finnish Institute for Health and Welfare

FINLAND
View details

Kala Visvanathan

Professor

Johns Hopkins University

UNITED STATES
View details

Jessica Petrick

Boston University

UNITED STATES
View details

Daniel D. Buchanan

Senior Research Fellow

University of Melbourne

AUSTRALIA
View details

Michelle Cotterchio

Professor (status only)

University of Toronto

CANADA
View details

Christopher Li

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Annika Lindblom

Karolinska Institutet

SWEDEN
View details

Jochen Hampe

Scientific Speaker

Technische Universität Dresden

GERMANY
View details

Anshul Kundaje

Associate Professor

Stanford University

UNITED STATES
View details

Mark Jenkins

University of Melbourne

AUSTRALIA
View details

Peter T. Campbell

Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Graham Giles

Head of Research

-

AUSTRALIA
View details

Michael Hoffmeister

Professor of Epidemiology, Group leader, Deputy divison head

German Cancer Research Center (DKFZ)

GERMANY
View details

Amanda Toland

Ohio State University

UNITED STATES
View details

Volker Arndt

Group leader

Deutsches Krebsforschungszentrum

GERMANY
View details

Elizabeth Barry

Associate Professor

Dartmouth College Geisel School of Medicine

UNITED STATES
View details

Pavel Vodička

senior researcher

Charles University

CZECH REPUBLIC
View details

Jennifer Ose

Professorin (W2)

Hochschule Hannover

GERMANY
View details